On 01.07.2019, the 2018 Drug Review Annual Report was released. Of the grand sum of 9,796 registration applications reviewed and approved in 2018, 7,988 were subject to technical review and 1,808 to direct administrative approval.
On 30.10.2018, the NMPA (former NMPA) issued guidelines for the approval process of clinically urgent new drugs (NMPA No. 79-2018). The product range, selection criteria, review procedure, and requirements for the application documents were specified.